ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Scilex Holding Company (SCLX) stock declined over -7.13%, trading at $4.82 on NASDAQ, down from the previous close of $5.19. The stock opened at $5.10, fluctuating between $4.80 and $5.30 in the recent session.
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Employees | 115 |
Beta | 1.14 |
Sales or Revenue | $46.74M |
5Y Sales Change% | 1.407% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep